The world market for toxicogenomics technologies is set to grow
strongly over the next five years, but needs the catalyst of
recognition by regulatory authorities.
IBM has introduced its new InsightLink software, an application to
help pharma companies create searchable online databases that will
enable more sharing of research knowledge.
A UK programme aimed at identifying the environmental, health and
safety, ethical and societal implications of nanotechnology has
appointed a working group to oversee the effort.
Argonaut sells its HPLC business to Grace Vydac as it refocuses on
supplying consumables for companies working on drug discovery.
Reports reduced losses in first half.
UK software company Intelligensys has launched a new product that
promises a step forward in the application of artificial
intelligence technologies to pharmaceutical formulation and design.
Iceland's deCODE genetics has initiated high-throughput screening
on its Neuregulin 1 pathway targets in schizophrenia in
collaboration with partner Roche.
GlaxoSmithKline has opened an ultra-high-throughput screening
facility at its site in Tres Cantos, Spain, marking a significant
milestone in the company's bid to develop a more industrialised
approach to the process of drug discovery.
The UK has launched a new study to examine in detail the benefits
and risks of nanotechnology and make sure that any necessary
regulatory framework is in place early on
IBM in the UK and US based IDBS, a provider of data management,
analysis and decision-making software for drug discovery, this week
announced a global strategic alliance.
Genetics-based drug discovery company CompleGen is to supply Berlex
Biosciences, a US affiliate of German company Schering, with a high
throughput assay system for discovery of compounds active against a
novel target identified by...
Pharmaceutical researchers used to begin their evaluation of drug
leads by looking at affinity and potency, but a
genomics/informatics-based research culture is now growing which is
starting to impinge on this classical mode, says...
Scientists in Australia report this week that they have developed a
powerful software modelling tool, MolSAR, which could have the
potential to reduce drug development costs by up to €28 million per
drug.
British Biotech, once the darling of the UK biotechnology industry
but now suffering the after-effects of a string of major drug
development failures, is having another go at bolstering its
pipeline via a merger with fellow UK company...
An Edinburgh-based marine biotech business has been given a £50,000
(€73 000) boost in its bid to scour tidal areas such as rock pools
to find and develop new drugs and antibiotics, including a new
compound found to be active against...
US demand for combinatorial chemistry products and services is set
to increase by more than twelve per cent annually to reach $4
billion (€3.7bn) in 2006, according to a new report from market
analyst the Freedonia group.
